Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis

Oncogene. 2001 Mar 1;20(9):1063-75. doi: 10.1038/sj.onc.1204141.

Abstract

Apoptosis in response to cellular stress such as treatment with cytotoxic drugs is mediated by effector caspases (caspase-3) which can be activated by different initiator pathways. Here, we report on a cell type specific triggering of death receptor and/or mitochondrial pathways upon drug treatment. In type I cells (BJAB), both the receptor and the mitochondrial pathway were activated upon drug treatment, since blockade of either the receptor pathway by overexpression of dominant negative FADD (FADD-DN) or of the mitochondrial pathway by overexpression of Bcl-X(L) only partially inhibited apoptosis. Drug treatment induced formation of a FADD- and caspase-8-containing CD95 death-inducing signaling complex (DISC) in type I cells resulting in activation of caspase-8 as the most apical caspase. In contrast, in type II cells (Jurkat), apoptosis was predominantly controlled by mitochondria, since overexpression of Bcl-2 completely blocked drug-induced apoptosis, while overexpression of FADD-DN had no protective effect. In these cells, caspases including caspase-8 were activated by mitochondria-driven signaling events and no DISC was detected despite expression levels of CD95, FADD and caspase-8 proteins comparable to type I cells. Likewise, drug-induced CD95 aggregation was predominantly found in type I cells. Bid was cleaved prior to mitochondrial alterations in type I cells providing a molecular link between caspase-8 activation and mitochondrial perturbations, whereas in type II cells, Bid was cleaved downstream of mitochondria. Our findings of a cell type specific response to cytotoxic drugs have implications for the identification of molecular parameters for chemosensitivity or resistance in different tumor cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing*
  • Amino Acid Chloromethyl Ketones / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • BH3 Interacting Domain Death Agonist Protein
  • Blotting, Western
  • Bongkrekic Acid / pharmacology
  • Carrier Proteins / metabolism*
  • Caspase Inhibitors
  • Caspases / metabolism
  • Cysteine Proteinase Inhibitors / pharmacology
  • Cytochrome c Group / metabolism
  • Doxorubicin / pharmacology*
  • Drug Resistance
  • Fas-Associated Death Domain Protein
  • Gene Expression / drug effects
  • Humans
  • Jurkat Cells / drug effects*
  • Membrane Potentials
  • Mitochondria / metabolism*
  • Mutation
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / physiology
  • Signal Transduction / physiology
  • Tumor Cells, Cultured / drug effects
  • bcl-X Protein
  • fas Receptor / metabolism*

Substances

  • Adaptor Proteins, Signal Transducing
  • Amino Acid Chloromethyl Ketones
  • Antineoplastic Agents
  • BCL2L1 protein, human
  • BH3 Interacting Domain Death Agonist Protein
  • BID protein, human
  • Carrier Proteins
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Cytochrome c Group
  • FADD protein, human
  • Fas-Associated Death Domain Protein
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-X Protein
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • fas Receptor
  • Bongkrekic Acid
  • Doxorubicin
  • Caspases